vs
Aligos Therapeutics, Inc.（ALGS）与艾伯维（ARGX）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Aligos Therapeutics, Inc.的14636.1倍（$2.5B vs $169.0K）。艾伯维净利率更高（35.5% vs -11763.9%，领先11799.4%）。艾伯维同比增速更快（83.2% vs -72.1%）
Aligos Therapeutics是一家临床阶段生物制药企业，专注于开发针对流行性肝病与病毒感染的新型靶向疗法，核心管线覆盖慢性乙型肝炎、非酒精性脂肪性肝炎等适应症，通过自主研发推进药物落地，满足全球未被满足的医疗需求。
艾伯维是总部位于美国伊利诺伊州北芝加哥的制药企业，研发生产的药物覆盖多种疾病治疗领域，可满足多元临床需求，致力于为全球不同病症的患者提供可靠的治疗方案选择。
ALGS vs ARGX — 直观对比
营收规模更大
ARGX
是对方的14636.1倍
$169.0K
营收增速更快
ARGX
高出155.3%
-72.1%
净利率更高
ARGX
高出11799.4%
-11763.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $169.0K | $2.5B |
| 净利润 | $-19.9M | $877.2M |
| 毛利率 | — | 89.5% |
| 营业利润率 | -12907.7% | 28.9% |
| 净利率 | -11763.9% | 35.5% |
| 营收同比 | -72.1% | 83.2% |
| 净利润同比 | 75.8% | 1.3% |
| 每股收益（稀释后） | $4.23 | $13.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALGSARGX
| Q4 25 | $169.0K | $2.5B | ||
| Q3 25 | $741.0K | — | ||
| Q2 25 | $965.0K | $1.8B | ||
| Q1 25 | $311.0K | — | ||
| Q4 24 | $606.0K | $1.4B | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | $1.1M | $901.9M | ||
| Q1 24 | $694.0K | — |
净利润ALGSARGX
| Q4 25 | $-19.9M | $877.2M | ||
| Q3 25 | $-31.5M | — | ||
| Q2 25 | $-15.9M | $414.8M | ||
| Q1 25 | $43.1M | — | ||
| Q4 24 | $-82.2M | $865.6M | ||
| Q3 24 | $-19.3M | — | ||
| Q2 24 | $5.1M | $-32.5M | ||
| Q1 24 | $-34.9M | — |
毛利率ALGSARGX
| Q4 25 | — | 89.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 89.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 90.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 89.4% | ||
| Q1 24 | — | — |
营业利润率ALGSARGX
| Q4 25 | -12907.7% | 28.9% | ||
| Q3 25 | -3827.4% | — | ||
| Q2 25 | -1924.0% | 19.2% | ||
| Q1 25 | -6187.5% | — | ||
| Q4 24 | -3393.2% | 8.7% | ||
| Q3 24 | -1610.5% | — | ||
| Q2 24 | -2489.5% | -15.4% | ||
| Q1 24 | -3176.7% | — |
净利率ALGSARGX
| Q4 25 | -11763.9% | 35.5% | ||
| Q3 25 | -4256.0% | — | ||
| Q2 25 | -1643.8% | 23.4% | ||
| Q1 25 | 13854.7% | — | ||
| Q4 24 | -13556.1% | 64.1% | ||
| Q3 24 | -1540.7% | — | ||
| Q2 24 | 477.0% | -3.6% | ||
| Q1 24 | -5023.5% | — |
每股收益（稀释后）ALGSARGX
| Q4 25 | $4.23 | $13.25 | ||
| Q3 25 | $-3.04 | — | ||
| Q2 25 | $-1.53 | $6.32 | ||
| Q1 25 | $-2.11 | — | ||
| Q4 24 | $-13.10 | $13.33 | ||
| Q3 24 | $-3.07 | — | ||
| Q2 24 | $0.81 | $-0.55 | ||
| Q1 24 | $-5.58 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.8M | $3.5B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $53.5M | $7.3B |
| 总资产 | $88.5M | $8.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALGSARGX
| Q4 25 | $77.8M | $3.5B | ||
| Q3 25 | $99.1M | — | ||
| Q2 25 | $122.9M | $2.1B | ||
| Q1 25 | $137.9M | — | ||
| Q4 24 | $56.9M | $1.5B | ||
| Q3 24 | $74.9M | — | ||
| Q2 24 | $94.5M | $1.4B | ||
| Q1 24 | $112.7M | — |
总债务ALGSARGX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $11.0M | ||
| Q1 24 | — | — |
股东权益ALGSARGX
| Q4 25 | $53.5M | $7.3B | ||
| Q3 25 | $71.8M | — | ||
| Q2 25 | $101.9M | $6.1B | ||
| Q1 25 | $116.4M | — | ||
| Q4 24 | $-29.0M | $5.5B | ||
| Q3 24 | $50.1M | — | ||
| Q2 24 | $67.2M | $4.3B | ||
| Q1 24 | $59.8M | — |
总资产ALGSARGX
| Q4 25 | $88.5M | $8.7B | ||
| Q3 25 | $109.8M | — | ||
| Q2 25 | $134.7M | $7.2B | ||
| Q1 25 | $150.7M | — | ||
| Q4 24 | $70.1M | $6.2B | ||
| Q3 24 | $88.4M | — | ||
| Q2 24 | $108.8M | $4.8B | ||
| Q1 24 | $127.9M | — |
负债/权益比ALGSARGX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-21.7M | $323.3M |
| 自由现金流经营现金流 - 资本支出 | — | $322.4M |
| 自由现金流率自由现金流/营收 | — | 13.0% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | 0.37× |
| 过去12个月自由现金流最近4个季度 | — | $594.5M |
8季度趋势，按日历期对齐
经营现金流ALGSARGX
| Q4 25 | $-21.7M | $323.3M | ||
| Q3 25 | $-24.3M | — | ||
| Q2 25 | $-15.5M | $361.8M | ||
| Q1 25 | $-20.9M | — | ||
| Q4 24 | $-18.4M | $41.9M | ||
| Q3 24 | $-20.1M | — | ||
| Q2 24 | $-19.5M | $-124.7M | ||
| Q1 24 | $-22.7M | — |
自由现金流ALGSARGX
| Q4 25 | — | $322.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $356.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $40.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-125.5M | ||
| Q1 24 | — | — |
自由现金流率ALGSARGX
| Q4 25 | — | 13.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 20.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -13.9% | ||
| Q1 24 | — | — |
资本支出强度ALGSARGX
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | — |
现金转化率ALGSARGX
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.87× | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
